DE60201437D1 - 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten - Google Patents

2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten

Info

Publication number
DE60201437D1
DE60201437D1 DE60201437T DE60201437T DE60201437D1 DE 60201437 D1 DE60201437 D1 DE 60201437D1 DE 60201437 T DE60201437 T DE 60201437T DE 60201437 T DE60201437 T DE 60201437T DE 60201437 D1 DE60201437 D1 DE 60201437D1
Authority
DE
Germany
Prior art keywords
chromanderivates
adrene
beta
substituted
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60201437T
Other languages
English (en)
Other versions
DE60201437T2 (de
Inventor
J O'connor
H Ladouceur
H Bullock
Ann-Marie Campbell
Miao Dai
Robert Dally
Jacques Dumas
N Hatoum-Mokdad
Uday Khire
Wendy Lee
Qingjie Liu
B Lowe
R Magnuson
Ning Qi
E Shelekhin
Quanrong Shen
A Smith
Ming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of DE60201437D1 publication Critical patent/DE60201437D1/de
Application granted granted Critical
Publication of DE60201437T2 publication Critical patent/DE60201437T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60201437T 2001-04-23 2002-04-22 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten Expired - Fee Related DE60201437T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US285719P 2001-04-23
US32451801P 2001-09-26 2001-09-26
US324518P 2001-09-26
PCT/US2002/012940 WO2002085891A1 (en) 2001-04-23 2002-04-22 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

Publications (2)

Publication Number Publication Date
DE60201437D1 true DE60201437D1 (de) 2004-11-04
DE60201437T2 DE60201437T2 (de) 2005-12-15

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60201437T Expired - Fee Related DE60201437T2 (de) 2001-04-23 2002-04-22 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten

Country Status (9)

Country Link
US (3) US6660752B2 (de)
EP (1) EP1389202B1 (de)
JP (1) JP2004532227A (de)
AR (1) AR035858A1 (de)
DE (1) DE60201437T2 (de)
DO (1) DOP2002000385A (de)
ES (1) ES2230487T3 (de)
PE (1) PE20021073A1 (de)
WO (1) WO2002085891A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AU2005238179B2 (en) * 2004-05-05 2010-08-26 F. Hoffmann-La Roche Ag Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
WO2006066756A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
DE602005009977D1 (de) * 2004-12-21 2008-11-06 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
BRPI0516381A (pt) * 2004-12-21 2008-09-02 Hoffmann La Roche derivados de cromano e seu uso como ligandos de receptor de 5-ht
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
ATE455755T1 (de) * 2004-12-21 2010-02-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen
TW200640931A (en) 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
JP2009514828A (ja) * 2005-11-03 2009-04-09 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６阻害剤としてのアリールスルホニルクロマン類、タンパク質キナーゼ阻害剤としてのインドリルマレイミド誘導体
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
JP2009541248A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホンアミジルテトラリン誘導体及びそれらの使用
EP2035370A2 (de) * 2006-06-20 2009-03-18 F. Hoffmann-Roche AG Tetralin- und indanderivate und ihre verwendung
EP2041079A1 (de) * 2006-06-20 2009-04-01 F. Hoffmann-Roche AG Arylsulfonylnaphthalinderivate und anwendungen davon
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
UA122519C2 (uk) * 2013-01-09 2020-11-25 Басф Агро Б.В. Спосіб одержання триазольної сполуки
WO2014207648A1 (en) * 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
EP3019013B1 (de) 2013-07-08 2020-12-23 BASF Agro B.V. Zusammensetzungen enthaltend eine triazolverbindung und ein biopestizid
EA037646B1 (ru) * 2013-12-12 2021-04-27 Басф Агро Б.В. Способ получения замещенных триазолов
EP3160229A1 (de) 2014-06-25 2017-05-03 BASF Agro B.V. Pestizidzusammensetzungen
CN106660979B (zh) 2014-07-08 2020-07-07 巴斯夫农业公司 制备取代的环氧乙烷类和三唑类的方法
AP2017009724A0 (en) 2014-07-17 2017-01-31 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
BR112017009282A2 (pt) 2014-11-07 2018-01-30 Basf Se misturas fungicidas, composição pesticida, métodos para controlar pragas fitopatogênicas, para melhorar a fitossanidade e para proteção de material de propagação de plantas contra pragas, e, material de propagação de plantas.
BR112017023932A2 (pt) 2015-05-08 2018-07-17 Basf Agro Bv processo para a preparação de epóxido de terpinoleno
CN107848922A (zh) 2015-05-08 2018-03-27 巴斯夫农业公司 柠檬烯‑4‑醇的制备方法
EP3383388B1 (de) * 2015-11-30 2021-04-14 Merck Sharp & Dohme Corp. Arylacylsulfonamide als blt1-antagonisten
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3429357A1 (de) 2016-03-16 2019-01-23 Basf Se Verwendung von tetrazolinonen zur bekämpfung phytopathogener pilze in getreide
BR112018068705B1 (pt) 2016-03-16 2022-09-06 Basf Se Método para controlar fungos fitopatogênicos
US11425909B2 (en) 2016-03-16 2022-08-30 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
CN109311835A (zh) 2016-06-15 2019-02-05 巴斯夫农业公司 环氧化四取代烯烃的方法
MX2018015765A (es) 2016-06-15 2019-08-29 Basf Agro Bv Proceso para la epoxidacion de un alqueno tretrasustituido.
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
ATE25251T1 (de) 1981-11-12 1987-02-15 Fisons Plc Anti srs-a carbonsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische formulierungen.
EP0091749A3 (de) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
EP0703911B1 (de) 1993-06-14 1997-07-02 Pfizer Inc. Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規２−アミノ−１−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (de) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclische Beta-3 adrenergische Angonisten
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
CA2278739A1 (en) 1997-01-28 1998-07-30 Emma R. Parmee Thiazole benzenesulfonamides as .beta.3 agonists for the treatment of diabetes and obesity
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
CN1284952A (zh) * 1997-12-19 2001-02-21 美国拜尔公司 用作β3肾上腺素能受体激动剂的羧基取代苯并二氢吡喃类衍生物
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6393316B1 (en) * 1999-05-12 2002-05-21 Medtronic, Inc. Method and apparatus for detection and treatment of cardiac arrhythmias
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Also Published As

Publication number Publication date
EP1389202A1 (de) 2004-02-18
US6660752B2 (en) 2003-12-09
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
US6919371B2 (en) 2005-07-19
WO2002085891A1 (en) 2002-10-31
ES2230487T3 (es) 2005-05-01
US20050215594A1 (en) 2005-09-29
EP1389202B1 (de) 2004-09-29
JP2004532227A (ja) 2004-10-21
DOP2002000385A (es) 2004-01-31
DE60201437T2 (de) 2005-12-15
PE20021073A1 (es) 2002-12-12
AR035858A1 (es) 2004-07-21

Similar Documents

Publication Publication Date Title
DE60201437D1 (de) 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten
ATE448238T1 (de) 3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE50213525D1 (de) Substituierte 2, 6-diamino-3, 5-dicyano-4-aryl-pyridine und ihre verwendung als adenosinrezeptor selektive liganden
DE50208895D1 (de) Substituierte 2-thio-3, 5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE50210986D1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
NO20041176L (no) Nye 4,5-dihydro- 1H-pyrazolderivater med CB1-antagonistisk aktivitet
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
DE60205100D1 (de) DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
DK1361880T3 (da) 6-substituerede pyrido-pyrimidiner
PT1373216E (pt) Derivados de 4,5-diidro-1h-pirazol que possuem actividade antagonista de cb1
DE50204779D1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine mit adenosinrezeptor-bindender wirkung und ihre verwendung als herz-kreislauf-mittel
NO20034929D0 (no) 4-amino-5-fenyl-7-cyklobutylpyrrol(2,3-D)pyrimidinderivater
BR0216099B1 (pt) "conjunto de desgaste".
CU23053A3 (es) 1,2,3,4-tetrahidroquinlinas 2-sustituidas 4-amino sustituidas
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE388937T1 (de) Agonisten des cannabinoidrezeptors
ATE287883T1 (de) Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
AU2002360733A8 (en) Substituted 4,9-dihydrocyclopenta(imn)phenanthridine-5-ones derivatives thereof and their uses

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee